ADM, a global leader in innovative solutions from nature, has announced findings from a recent clinical study on the effects of PRIOME®MH, a postbiotic derived from Bifidobacterium animalis subsp. lactis CECT 8145, in adult dogs. The study revealed that the postbiotic supports healthy blood sugar levels, with a significant reduction in postprandial blood glucose levels observed after a normal kibble meal compared to a placebo, particularly during a weight loss phase. Additionally, lower levels of gamma-glutamyl transferase, a liver function marker, were noted during a weight gain phase. The results suggest a potential role for PRIOME®MH in supporting canine metabolic health, contributing to the growing interest in functional pet nutrition.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.